Royal Sense
ROYALSENSELTD NSE
Royal Sense
HealthcareNSE: ROYALSENSELTD BSE: ROYAL Medical Equipment
Key Fundamentals
SMEMedical EquipmentHealthcareMarket Cap
₹50.80 Cr
Volatility
Moderate
P/E Ratio
7.1
EBITDA
₹10.96 Cr
Return on Equity
22.83%
Debt to Equity
0.33
Book Value
₹71.06
EPS
₹3.24
52W High
₹270
52W Low
₹83.1
Tapetide Score
Data-driven rating, 0–100. How it works →
Key Insights
Weaknesses
1- Though the company is reporting repeated profits, it is not paying out dividend
Growth Rate
Revenue Growth
67.28% lower than
3Y
Net Income Growth
13.02% lower than
3Y
Cash Flow Change
131% higher than
3Y
ROE
162% higher than
3Y
ROCE
158% level than
3Y
EBITDA Margin (Avg.)
-26.97% lower than
3Y
Quarterly Results
| Particulars | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Sales | 11 | 22 | 40 | 43 | 60 |
| Expenses | 6 | 19 | 34 | 38 | 55 |
| Operating Profit | 5 | 3 | 6 | 6 | 5 |
| OPM % | 48% | 14% | 14% | 13% | 9% |
| Other Income | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 |
| PBT | 5 | 3 | 6 | 5 | 5 |
| Tax % | 7% | 25% | 29% | 25% | 32% |
| Net Profit | 5 | 2 | 4 | 4 | 3 |
| EPS in Rs | 9.94 | 4.86 | 7.97 | 7.59 | 5.79 |
Profit & Loss
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Sales | 18 | 62 | 103 |
| Expenses | 16 | 53 | 92 |
| Operating Profit | 2 | 9 | 11 |
| OPM % | 13% | 14% | 11% |
| Other Income | 0 | 0 | 0 |
| Interest | 0 | 0 | 1 |
| Depreciation | 0 | 0 | 0 |
| PBT | 2 | 9 | 10 |
| Tax % | 28% | 27% | 28% |
| Net Profit | 2 | 6 | 7 |
| EPS in Rs | 3.24 | 12.74 | 13.36 |
| Div. Payout % | 0% | 0% | 0% |
Balance Sheet
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity Capital | 5 | 5 | 5 |
| Reserves | 13 | 23 | 35 |
| Borrowings | 2 | 3 | 13 |
| Other Liabilities | 1 | 5 | 8 |
| Total Liabilities | 21 | 36 | 61 |
| Fixed Assets | 0 | 2 | 2 |
| CWIP | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 |
| Other Assets | 20 | 33 | 59 |
| Total Assets | 21 | 36 | 61 |
Cash Flow
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Operating | -4 | 1 | -13 |
| Investing | -1 | -2 | 0 |
| Financing | 13 | 3 | 5 |
| Net Cash Flow | 9 | 2 | -8 |
| Free Cash Flow | -4 | 0 | -14 |
| CFO/OP | -144 | 21 | -110 |
Ratios
| Particulars | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Debtor Days | 66 | 86 | 101 |
| Inventory Days | — | — | 63 |
| Days Payable | — | — | 10 |
| Cash Conversion Cycle | 66 | 86 | 153 |
| Working Capital Days | 187 | 86 | 126 |
| ROCE % | — | 35% | 26% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Royal Sense insights
49 extracted metrics + investor summaries across FY13–FY26.
Documents
1
Clarification sought from Royal Sense Ltd
1 Sep - Exchange has sought clarification from Royal Sense Ltd on September 01, 2026 with reference to significant movement in price, in order to ensure that investors … 1 Sep - Exchange has sought clarification from Royal Sense Ltd on September 01, 2026 with reference to significant movement in price, in order to ensure that investors …
2
Non-Applicability Of Disclosures Of Large Corporates For The Financial Year Ended On 31St March, 2026
30 Apr - Royal Sense says Large Corporate disclosure framework is not applicable for FY ended 31 March 2026. 30 Apr - Royal Sense says Large Corporate disclosure framework is not applicable for FY ended 31 March 2026.
3
Non-Applicability Of Disclosures Of Large Corporates For The Financial Year Ended On 31St March, 2026
30 Apr - Royal Sense says Large Corporate disclosure framework is not applicable for FY ended 31 March 2026. 30 Apr - Royal Sense says Large Corporate disclosure framework is not applicable for FY ended 31 March 2026.
4
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
27 Apr - Royal Sense launched 17 pharmaceutical products for domestic sale from 27 April 2026. 27 Apr - Royal Sense launched 17 pharmaceutical products for domestic sale from 27 April 2026.
5
Disclosure Under Regulation 30 Of The SEBI (LODR) Regulations, 2015.
13h - Royal Sense launched 17 pharmaceutical products for domestic sale from 27 April 2026. 13h - Royal Sense launched 17 pharmaceutical products for domestic sale from 27 April 2026.
5
Announcement Under Regulation 30 Of SEBI(LODR)Regulations 2015 - Clarification On Price Movement 1 Sept 2026
General_Announcements
Frequently Asked Questions about Royal Sense
What does Royal Sense Ltd do?
Incorporated in 2023, Royal Sense Ltd specializes in medical device and pharmaceutical trading.[1]
Where is Royal Sense Ltd (544143) listed?
Royal Sense Ltd trades as ROYALSENSELTD on the NSE and under code ROYAL on the BSE.
Which sector does Royal Sense Ltd belong to?
Royal Sense Ltd is classified under the Healthcare sector, in the Medical Equipment industry.
What is the market capitalisation of Royal Sense Ltd?
Royal Sense Ltd has a market capitalisation of ₹50.8 Cr, which places it in the Small Cap band.
What is the PE ratio of Royal Sense Ltd?
Royal Sense Ltd trades at a PE ratio of 7.10, on earnings per share of ₹3.24, against a book value of ₹71.06 per share.
What is the 52-week high and low of Royal Sense Ltd?
Over the last 52 weeks Royal Sense Ltd has traded between ₹83.1 and ₹270.
What is the Return on Equity (ROE) of Royal Sense Ltd?
Royal Sense Ltd reported a return on equity of 22.83%. Its debt-to-equity ratio is 0.33.
Company Information
Incorporated in 2023, Royal Sense Ltd specializes in medical device and pharmaceutical trading.[1]
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/544143.md for Royal Sense Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.
Append .md to any Tapetide URL for the
same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live,
structured queries instead of documents, use our MCP server.